Insmed Stock Surges on Positive Pulmonary Hypertension Trial Results
TL;DR Summary
Insmed's experimental therapy for pulmonary arterial hypertension succeeded in a mid-stage trial, causing shares of competitors Liquidia and United Therapeutics to fall in premarket trading.
Topics:business#healthcare#insmed#liquidia#mid-stage-trial#pulmonary-arterial-hypertension#united-therapeutics
- Liquidia stock, United Therapeutics stock fall on Insmed data Seeking Alpha
- Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results Yahoo Finance
- Insmed's 'unprecedented' phase 2 PAH win sends stocks soaring as the race to phase 3 kicks off Fierce Pharma
- Biotech Hits A 'Home Run' And Slams Its Two Key Rivals Investor's Business Daily
- Insmed Stock Soars on Experimental Hypertension Drug Trial Results Barron's
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
72%
89 → 25 words
Want the full story? Read the original article
Read on Seeking Alpha